1. Introduction {#s1}
===============

Gilles de la Tourette Syndrome (TS) is a childhood onset neuropsychiatric disorder characterized by a multitude of motor and vocal tics that last longer than a year. Its international prevalence has been estimated to be approximately 1% (Robertson et al., [@B25]). A recent systematic review and meta-analysis on the population prevalence of TS, refined its prevalence estimate in children to 0.3--1% (Scharf et al., [@B26]). It presents a significant gender bias, with 73% of its patients being male, and the male patients being more likely to develop comorbid disorders (Robertson et al., [@B24]). TS is often associated with other neuropsychiatric disorders, including Attention Deficit/Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), depression and anxiety (Robertson, [@B23]).

The first genome-wide association study (GWAS) on TS was undertaken by the Tourette Syndrome Association International Consortium for Genetics (TSAICG) (Scharf et al., [@B27]). In their primary analysis, no SNPs achieved an association *p*-value of genome-wide significance, however this study provided the basis for subsequent studies, as the top signals that attained a *p* \< 10^−3^ were found to be significantly enriched for functional variants. The Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI) undertook a replication (Paschou et al., [@B20]) of the first GWAS study, by selecting the top LD-independent SNPs and additional SNPs singificantly enriched in eQTL or mQTLs for genotyping in 609 European TS patients and 610 ancestry-matched controls, recruited from different European countries and Canada. This replication study enriched the significance of the selected SNPs and provided more evidence toward the genetic aetiology of TS.

On the other hand, initial GWAS attempts on ADHD also did not yield genome-wide significant results (Neale et al., [@B16]; Mick et al., [@B15]; Neale et al., [@B17]; Lesch et al., [@B12]). To that end, a meta-analysis was conducted by Neale et al. ([@B18]), aggregating the results of the previous GWAS projects and meta-analyzing them. This meta-analysis could not produce any significant results either, but, similar to the TS GWAS, it set the groundwork for the elucidation of the genetic background of ADHD.

The relationship of TS with ADHD is well established (Karagiannidis et al., [@B9]). Individuals with ADHD commonly present tics, and in individuals with TS and tics, ADHD is a significant commorbidity. ADHD occurs in a significant proportion of TS patients, ranging from 21 to 90% in studied cohorts (Robertson, [@B23]). This phenotypic association is a major indication of a common genetic background between the two disorders. Furthermore, a recent study investigating the genetic correlation among neuropsychiatric and neurological disease based on GWAS results for each disorder, also recovered a genetic correlation between TS and ADHD (Anttila et al., [@B2]).

This is the first study to attempt to identify a shared genetic component between TS and ADHD. We used summary statistics from the latest large-scale genomic efforts to unravel the genetic background of TS and ADHD and derived the combined effects of shared polymorphisms between the two datasets, highlighting genes and pathways that may play a role in the shared etiology between the two disorders.

2. Materials and methods {#s2}
========================

2.1. Data sources
-----------------

For our study we focused on the combination of the known effects of SNPs on the phenotypes of TS and ADHD.

Scharf et al in their study (Scharf et al., [@B27]) performed a GWAS and meta-analysis on a total of 1285 cases and 4964 ancestry-matched controls of European ancestry, genotyped on 484,295 SNPs. The dataset was analyzed in three split cohorts and was subsequently meta-analyzed. The study reported 552 SNPs associated with TS that acquired a *p* \< 10^−3^.

We acquired the ADHD meta-GWAS whole-genome summary statistics from the study conducted by the ADHD subgroup of the Psychiatric GWAS consortium (Neale et al., [@B18]; Cross-Disorder Group of the Psychiatric Genomics Consortium, [@B5]). The total sample size consisted of 896 cases, 2455 controls and 2064 trios genotyped and then imputed to 1,230,536 SNPs.

We used the publically available top SNPs with a *p* \< 10^−3^ associated with TS (Scharf et al., [@B27]) and meta-analyzed them with the results of the ADHD meta-analysis (Neale et al., [@B18]; Cross-Disorder Group of the Psychiatric Genomics Consortium, [@B5]). We identified 489 SNPs that were overlapping between the two sources to proceed with the meta-analysis.

2.2. Meta-analytical procedure
------------------------------

We combined the effects of the SNPs in each phenotype, following a meta-analytic approach, assuming a fixed-effects model, using the Z-Scores as the effect and the number of cases in each study as the weight. The heterogeneity of each analyzed SNP was assessed using Cochran\'s *Q*-test and *I*^2^ statistic. The analysis was performed using the METAL (Willer et al., [@B33]) software. The significance threshold was set using the Bonferroni correction for multiple testing.

2.3. Annotation and functional significance
-------------------------------------------

We proceeded to analyze the significant SNPs using the ENSEMBL Variant Effect Predictor (McLaren et al., [@B14]) to annotate and explore the possible functional characteristics of the associated variants. The genomic positions of the variants were converted to the GRCh38 assembly coordinates. For the investigation of the allelic frequencies, and the linkage disequilibrium (LD) patterns we used data from the 1000Genomes project (1000 Genomes Project Consortium et al., [@B1]) and the LDlink software (Machiela and Chanock, [@B13]). To investigate the association of the variants and their respective genes with tissue expression levels we used the GTEx portal (The GTEx Consortium, [@B30]) and the Expression Atlas database (Petryszak et al., [@B21]). The annotation and exploration of the genomic structure of the identified loci was further assisted by the use of LdOOKUP, developed by Shaun Purcell (<https://purces04.u.hpc.mssm.edu/ldookup/ldookup.cgi>).

We have uploaded all codes necessary to confirm our conclusions and they can be found at <https://github.com/ftsetsos/tsadhdmeta2016>.

3. Results {#s3}
==========

The meta-analysis produced 19 significant SNPs, out of the total 489 tested. The significance threshold was set using the Bonferroni correction for multiple testing, setting the significance level at a *p*-value of 0.0001022.

Of these 19 SNPs, five attained the lowest *p*-values, coupled with no evidence of confounding heterogeneity (*I*^2^ = 0). The tested SNPs that present the most significant heterogeneity (Het *p* \< 0.05) were the ones that had achieved a *p* \< 0.05 in the original ADHD meta-analysis. The annotation showed that the majority of the significant variants are located in introns, two are in regulatory regions, while three are intergenic.

The first and third top hits (rs1866863, *p*:3.23E-07 and rs2458304, *p*:2.54E-06) reside on a LD-block of 54.19 kb on the 6p24.1 region. They show significant linkage disequilibrium between them (*D*′: 0.909, *R*^2^: 0.725). The former is a variant located in the regulatory region downstream of the TBC1D7 gene, and the latter is an intron variant in the same gene. Both are in LD with the rs499818 eQTL (*R*^2^: 0.59 and 0.48 respectively), suggesting an interplay with the expression levels of the gene.

Chromosome 4 hosts the second (rs2705462, *p*:1.44E-06), the fourth (rs17561798, *p*:9.89E-06), and two lower-ranked variants(rs477897, *p*:8.65E-05 and rs2285084, *p*:1.00E-04), each residing in four distinct, LD-independent loci. The most significant variant, rs2705462, is located in the intergenic region upstream of the GUCY1A3 gene in the 4q32.1 region on a LD-block of 46.63 kb. The next variant, rs17561798, resides in the 4q23 region and is an intron variant inside the RAP1GDS1 gene. The variant rs477897 is located within an intron of ADD1 in the region 4p16.3 captures an area of 125.59 kb, implicating the genes H3BP2, ADD1, MFSD10, NOP14. The intron variant rs2285084 is located in the gene ANXA10. The gene is included in the locus 4q32.3 in a high LD region of 330.00 kb that contains also the genes ANXA10, DDX60, DDX60L.

The fifth most significant SNP, rs1650137 (*p*:1.76E-05), is located on 12q23.3 in an intron of the gene CHST11. This region is inside a LD-block that extends for 39.68 kb. The variant rs2246417 came up as the sixth most significant (*p*:1.95E-05), residing in the locus 21q22.3 in a LD-block of 16.29 kb, within an intron of the LINC00316 gene.

The variant rs11716445 (*p*: 8.01E-05) resides in the 3p21.31 region. This region is characterized by a very large area with an extended high-LD block of 1941.64 kb and it contains 70 genes, with the first genes being PLXNB1, CCDC51, TMA7, ATRIP, TREX1, and ending with HYAL2, TUSC2, RASSF1, ZMYND10, NPRL2. The variant itself is located in the intron of the RHOA gene. It is one of the lower-ranked variants that achieved minimal confounding by heterogeneity.

The locus 7p21.3 hosts the intergenic variants rs13244651 (*p*:4.11E-05) and rs17531553 (*p*:7.08E-05) that are part of a LD-block sized at 103.93 kb, albeit with no known genes close to them, and no strong suggestive results for any direct functional implication.

Two genomic regions on chromosome 9 are implicated by our results. A region of 58.16 kb in the 9p24.2 locus contains the variants rs1007021 (*p*: 4.38E-05) and rs1007022 (*p*:7.68E-05) in the introns of KCNV2, showing strong LD between them (*D*′: 1.000 *R*^2^:0.803). The region 9q31.1 contains the intergenic variant rs7858600 (*p*:5.30E-05) inside a region of 27.35 kb.

In the locus 10q21.1, the intergenic variant rs1896373 (*p*:7.46E-05) captures a region of 47.58 kb, in strong LD with the rs1919459 eQTL (*R*^2^: 0.97) that is associated with the regulation of DKK1. The variant rs4789936 (*p*:8.92E-05) is located in the 17q25.3 locsus, in a LD-region 34.19 kb, and is an intron variant of the gene TIMP2 while on it is non-coding exon variant in the gene CEP295NL. In the locus 16q12.1, the variant rs7203818 (*p*:1.01E-04) resides in a LD-block of 21.12 kb within an intron of ZNF423.

On chromosome 13, the LD-associated variants rs7336083 and rs9319159 (*D*′: 0.974 *R*^2^: 0.897) represent an LD-block of 292.34 kb and reside in the introns of the LINC00351 gene. The result is mostly driven by the *p*-value attained in the TS meta-analysis and there is evidence of significant confounding caused by heterogeneity.

We summarize the results of the meta-analysis on Table [1](#T1){ref-type="table"}. In Table [2](#T2){ref-type="table"}, we provide the annotation we generated for each significant variant, and in Table [3](#T3){ref-type="table"} we provide the LD regions associated with the variants. The full results of the meta-analysis on the 489 tested SNPs are described in more detail in the Supplementary Material.

###### 

**Significant results of the meta-analysis**.

  **SNP**      **Chromosome**   **Position**   **Allele**   **TS**     **ADHD**   **Meta**   **Direction**   ***I*^2^**   **Het *P*-value**
  ------------ ---------------- -------------- ------------ ---------- ---------- ---------- --------------- ------------ -------------------
  rs1866863    6                13336583       A            6.09E-04   1.51E-04   3.23E-07   --              0            0.9916
  rs2705462    4                155648650      T            8.30E-04   5.09E-04   1.44E-06   --              0            0.875
  rs2458304    6                13323663       A            3.74E-04   1.77E-03   2.54E-06   --              0            0.5818
  rs17561798   4                98314790       A            3.80E-04   6.01E-03   9.89E-06   --              0            0.4226
  rs1650137    12               104586532      A            4.01E-04   9.58E-03   1.76E-05   ++              0            0.3702
  rs2246417    21               45339588       T            2.54E-04   1.42E-02   1.95E-05   ++              13.7         0.2816
  rs9319159    13               85445305       T            1.15E-05   1.11E-01   3.77E-05   --              79.2         0.02837
  rs13244651   7                10308596       T            5.03E-05   6.18E-02   4.11E-05   ++              67.8         0.07797
  rs1007021    9                2723657        A            5.36E-05   6.26E-02   4.38E-05   ++              67.5         0.07919
  rs7858600    9                102764080      A            2.26E-04   3.42E-02   5.30E-05   ++              42.8         0.1859
  rs7336083    13               85429252       A            9.49E-06   1.71E-01   6.88E-05   --              82.3         0.01756
  rs17531553   7                10311703       A            9.40E-05   6.73E-02   7.08E-05   ++              64.5         0.09348
  rs1896373    10               52334599       T            3.46E-04   3.50E-02   7.46E-05   ++              35.8         0.2121
  rs1007022    9                2723761        A            8.85E-05   7.33E-02   7.68E-05   ++              66           0.08647
  rs11716445   3                49368662       A            7.95E-04   2.22E-02   8.01E-05   ++              0            0.336
  rs477897     4                168177763      A            3.10E-04   4.19E-02   8.65E-05   ++              42.5         0.1874
  rs4789936    17               78901892       T            7.12E-04   2.61E-02   8.92E-05   --              5.1          0.3047
  rs2285084    4                2904558        A            8.07E-04   2.66E-02   1.00E-04   --              1            0.3149
  rs7203818    16               49610387       A            4.03E-04   4.09E-02   1.01E-04   ++              37.1         0.2075

*Here we report the p-values attained in each study, the combined p-value after the meta-analysis and the direction of the effect. Alongside these statistics, we also present Cochran\'s I^2^ value and the heterogeneity p-value for each SNP*.

###### 

**Functional annotation of the significant SNPs of the meta-analysis**.

  **SNP**      **Chromosome**   **Position**   ***P*-value**   **Gene**     **Impact**          **Global Freq**   **EUR Freq**
  ------------ ---------------- -------------- --------------- ------------ ------------------- ----------------- --------------
  rs1866863    6                13336583       3.23E-07        TBC1D7       Regulatory region   A:0.4583          G:0.3907
  rs2705462    4                155648650      1.44E-06        GUCY1A3      Intergenic          T:0.2041          T:0.2893
  rs2458304    6                13323663       2.54E-06        TBC1D7       Intron              A:0.4287          G:0.3598
  rs17561798   4                98314790       9.89E-06        RAP1GDS1     Intron              G:0.0110          G:0.0398
  rs1650137    12               104586532      1.76E-05        CHST11       Intron              A:0.2911          A:0.2038
  rs2246417    21               45339588       1.95E-05        LINC00316    Intron              C:0.2428          C:0.1461
  rs9319159    13               85445305       3.77E-05        LINC00351    Intron              T:0.3259          T:0.3797
  rs13244651   7                10308596       4.11E-05        Intergenic   Intergenic          G:0.3724          G:0.4066
  rs1007021    9                2723657        4.38E-05        KCNV2        Intron              A:0.1388          A:0.0696
  rs7858600    9                102764080      5.30E-05        Intergenic   Intergenic          G:0.3694          A:0.4861
  rs7336083    13               85429252       6.88E-05        LINC00351    Intron              A:0.3311          A:0.3668
  rs17531553   7                10311703       7.08E-05        Intergenic   Intergenic          G:0.3746          G:0.4066
  rs1896373    10               52334599       7.46E-05        Intergenic   Regulatory region   T:0.4994          T:0.4513
  rs1007022    9                2723761        7.68E-05        KCNV2        Intron              A:0.0649          A:0.0567
  rs11716445   3                49368662       8.01E-05        RHOA         Intron              A:0.03115         A:0.1024
  rs477897     4                168177763      8.65E-05        ANXA10       Intron              G:0.1148          G:0.2256
  rs4789936    17               78901892       8.92E-05        CEP295NL     Intron              T:0.4407          T:0.5219
  rs2285084    4                2904558        1.00E-04        ADD1         Intron              G:0.2414          G:0.2087
  rs7203818    16               49610387       1.01E-04        ZNF423       Intron              A:0.2169          A:0.1581

*Here we present the genes in which the SNPs are located, along with the frequency of the alleles in global and european populations, according to 1000 Genomes*.

###### 

**LD-regions that are captured by the top SNPs in our study**.

  **SNP**      **Chromosome**   **Region**             **Length (kb)**   **Gene(s)**                   **eQTL**
  ------------ ---------------- ---------------------- ----------------- ----------------------------- ----------------------
  rs11716445   3                48446237.50387873      1941.64           PLXNB1;...NPRL2               --
  rs2705462    4                156557255\.156603882   46.63             GUCY1A3                       --
  rs477897     4                168980017\.169310018   330.00            ANXA10; DDX60; DDX60L         --
  rs2285084    4                2836195.2961783        125.59            SH3BP2; ADD1; MFSD10; NOP14   --
  rs1866863    6                13298395.13352581      54.19             TBC1D7                        1.7e-10 (rs499818)
  rs17531553   7                10255806.10359733      103.93            --                            --
  rs7858600    9                105517266\.105544614   27.35             --                            --
  rs1007021    9                2699874.2758034        58.16             KCNV2                         --
  rs1896373    10               54068904.54116478      47.58             DKK1                          2.18e-05 (rs1919459)
  rs1650137    12               104977289\.105016971   39.68             CHST11                        --
  rs7336083    13               85893863.86186202      292.34            --                            --
  rs7203818    16               49637407.49658524      21.12             ZNF423                        --
  rs4789936    17               76894415.76928600      34.19             TIMP2; LOC100653515           --
  rs2246417    21               46744358.46760648      16.29             --                            --

*Regions that are in linkage disequilibrium with the top SNPs, along with the range of genes residing in those regions and any linked known eQTLs. Genomic coordinates are in reference to the GRCh37 assembly*.

4. Discussion {#s4}
=============

This is the first study to identify shared genetic factors underlying TS and ADHD, two closely related and often co-occurring neuropsychiatric disorders (Karagiannidis et al., [@B9]). We meta-analyzed 489 of the top hit SNPs in the first TS GWAS, that had also been tested in ADHD published GWASs and meta-analysis. Our own meta-analysis highlights genes that may play a role in the shared etiology between TS and ADHD. 19 SNPs attained in the meta-analysis a *p*-value lower than the significance threshold, as denoted by the Bonferroni correction approach for multiple testing. All significant SNPs had the same direction of effect, which is indicative of a shared mechanism of disease development. A minority of those had not presented any association with ADHD in the original ADHD meta-analysis, with the resulting combined *p*-value being driven mostly by the *p*-value acquired from the TS study.

The five most significant SNPs had achieved moderate association *p*-values in the original ADHD study, and thus attained high *p*-values with no heterogeneity-based confounding in our meta-analysis, becoming strong candidates for the shared genomic background of the disorders.

TBC1D7 (TBC1 Domain Family, Member 7) is a prominent gene in our results, with two variants achieving the top and the third best *p*-values in our study. The top scoring SNP is located in a regulatory region downstream of the gene, while the third top is located within an intron of the gene. The associated variants have demonstrated linkage disequilibrium with a known eQTL for the expression of the gene, further substantiating their implication into the regulation of the expression profile of the gene. Expression profiling in Expression Atlas and GTEx show significant overexpression in the brain, the heart, the testis and in blood cells. The product of the gene is the third subunit of the TSC1-TSC2 complex with a Rheb-GAP activity, and is ubiquitously present in the complex (Dibble et al., [@B6]). An eQTL for TBC1D7 has been significantly associated with migraine and migraine without aura in a study of 23,285 individuals with migraine and 95,425 population-matched controls (Anttila et al., [@B3]). Interestingly, Anttila et al (Anttila et al., [@B2]) also picked up a genetic correlation between TS and migraine.

The presence of TBC1D7 in the TSC1/2 complex creates a suggestive functional link between the proteins. The role of the TSC1/2 complex is indicative of TBC1D7\'s role in the brain and neuropsychiatric disease, as an important component of the active complex. The TSC1 (Tuberous Sclerosis 1) and TSC2 (Tuberous Sclerosis 2) genes have an important role in the aetiology of Tuberous Sclerosis Complex (TSC). TSC is a neurodevelopmental disorder that typically presents with tumours of the brain, skin, heart, lungs, and kidneys, but also neurological disorders such as epilepsy, cognitive disability and autism. The TSC1/2 complex acts as an inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway which plays a central role in cell growth, proliferation, autophagy and thus also neurodevelopment (Henske et al., [@B8]). The TSC pathway regulates neuronal structure and function, and is sensitive to gene-dosage effects, showing degrees of haploinsufficiency (Tavazoie et al., [@B29]). TSC1 has also been implicated in bipolar disorder, without attaining genome-wide significance (Scott et al., [@B28]). Furthermore, TSC1 has been shown to have a neuroprotective role in hippocampal regions of the brain, protecting against ischemic events (Papadakis et al., [@B19]).

RAP1GDS1 (RAP1, GTP-GDP dissociation stimulator 1) is a GDP/GTP exchange protein with GTPase activity (Riess et al., [@B22]). It is located on chromosome 4 and is the third top locus to be implicated in the shared genetic background, with the associated variant residing in the intron of the gene. It is significantly overexpressed in brain and nervous tissues. RAP1GDS1 has been shown to interact with RHO (Ras homolog gene family, member A), that has also been implicated in this study, in a cascade involving interactions with multiple signaling proteins (Vikis et al., [@B31]; Berg et al., [@B4]; Hamel et al., [@B7]). CHST11 (carbohydrate chondroitin 4 sulfotransferase 11) is involved in the sulfation of chondroitin (Klppel, [@B10]), which is a key element of the brain matrix (Kwok et al., [@B11]). It is expressed in areas of the brain, including the hippocampus and the caudate nucleus. GUCY1A3 (Guanylate cyclase soluble subunit alpha-3) functions as the main receptor for nitric oxide, and has been implicated in Moyamoya disease, a disease causing constriction in arteries and brain ischemic events (Wallace et al., [@B32]).

5. Conclusion {#s5}
=============

We investigate, for the first time, the common genetic background between TS and ADHD on a genomewide scale and provide evidence that specific genes may underlie both disorders. The implicated variants lie on genes that appear to have a complex interplay between them. The main theme of the results is the Ras signaling cascade in the brain, with TBC1D7 and RAP1GDS1 being key elements of the brain signaling pathways. Interestingly, an additional theme emerging from the data, is related to brain ischemic response, with GUCY1A3 and the TSC1/2 complex (which includes TBC1D7) as implicated as factors. Intriguingly, one of our top hits, TBC1D7, implicates the mTOR signaling pathway and autophagy processes (Dibble et al., [@B6]). Furthermore, our analysis also points to CHST11, which has been shown to regulate the brain extracellular matrix, by affecting the chondroitin sulfation levels. Therefore, further investigation in the role of the respective genes in the shared genetic aetiology of TS and ADHD is warranted. Our results provide an intriguing insight into the shared mechanism of common neuropsychiatric disorders.
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